Hologic reports positive results of MammoSite trial

The study deals with the treatment efficacy, cosmetic results and toxicities of patients enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. The trial includes a total of 1,440 patients with early stage breast cancer, who were undergoing breast-conserving therapy and were treated with MammoSite between May 2002 and July 2004. Of the total, 87% of the patients had invasive breast cancer and 13% had been diagnosed with ductal carcinoma in situ (DCIS).

The authors presented a subset analysis of the first 400 cases enrolled in the study with a median follow-up of 37.5 months. The three-year actuarial rate of local or regional recurrence was less than 2% in this group. The percentage of breasts with good or excellent cosmetic results was 93% at 36 months. The authors also reported a three-year actuarial local control rate of 100% in the first 48 patients enrolled with DCIS. An analysis of the overall registry population with a median follow-up of 30.1 months, showed a two-year actuarial rate of local or regional recurrence of one percent; good or excellent cosmetic results of 94% at 24 months and a 10.6% rate of symptomatic seromas.